Mike Nally is the Chief Executive Officer of Generate Biomedicines and a CEO-Partner at Flagship Pioneering. Mike brings significant experience leading global organizations and is passionate about working with teams and partners to bring innovations to patients. Mike previously served as Chief Marketing Officer at Merck & Co. In this role, Mike was responsible for Global Marketing and Brand Strategy across a vast portfolio, exceeding $40B in revenue, of innovative medicines and vaccines. Prior to this role, Mike served as President of Global Vaccines at Merck, providing a broad portfolio of pediatric, adolescent, and adult vaccines to the world. In this position, Mike and his team worked to drive a dramatic increase in the reach and public health impact of vaccines, while delivering significant business growth. Additionally, Mike has led the company's business in Sweden and the UK, focusing on the development and implementation of innovative, customer-centered approaches that delivered improved business results and accelerated patient access to our medicines. He has also held a variety of positions in Commercial Operations, Business Development and Investor Relations. Geoffrey von Maltzahn is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies in therapeutics and agriculture. Geoffrey is a General Partner at Flagship Pioneering and has co-founded companies that represent, in aggregate, over $10 billion in public and private market capitalization. Through his role in Flagship Labs, Geoffrey has created companies that include Generate Biomedicines, Tessera Therapeutics, Indigo Agriculture, Sana Biotechnology (NASDAQ: SANA), Kaleido Biosciences (NASDAQ: KLDO), Seres Therapeutics (NASDAQ: MCRB), and Axcella Health (NASDAQ: AXLA). These are pioneering, respectively, generative biology, gene writing, plant microbiome products for crop improvement, engineered cells and cell-specific gene therapies, novel chemistries to drive the human microbiome, the first microbiome therapeutics, and amino acid-based drugs. Geoffrey recently served as founding CEO for Generate Biomedicines and currently serves as a Board Director. Additionally, he is Chief Executive Officer and Director of Tessera Therapeutics, Chief Innovation Officer and Director of Indigo, and Director of Kaleido Biosciences and Sana Biotechnology. He recently served as Chief Executive Officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, and as Kaleido’s Chief Executive Officer, where he led the company from inception to the launch of multiple clinical studies. Geoffrey also served as Chief Executive Officer of Indigo, where he led the development of the company’s plant microbiome platform and the discovery of the company’s first commercial products: Indigo Cotton, Indigo Wheat, Indigo Corn, and Indigo Soy, which are now used on over a million acres. Previously, Geoffrey was the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109, the first microbiome therapeutic to report positive phase 3 data, and built out the company’s discovery platform. Geoffrey has deep expertise in genome engineering, the microbiome, bioengineering, and nanotechnology. He is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles. Geoffrey has received a number of awards and honors, including Bloomberg 50's Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints News' 20 Biopharma Leaders Under 40; Boston Chamber of Commerce's Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related